CytoSorbents posts investor presentation outlining Q2 revenue, cash burn progress toward breakeven

Reuters2026/08/12 02:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CytoSorbents posted Q2 2026 revenue of USD 9.6 million, gross margin of 73%, operating cash burn of about USD 200,000.
Management targeted operating cash flow breakeven in the second half of 2026.
Core CytoSorb product sales reached a record USD 37.3 million on a trailing 12-month basis through June 30, 2026.
DrugSorb-ATR remained investigational in the US, with a new De Novo submission planned to pursue regulatory clearance.
The pivotal STAR-T randomized trial paper was published, supporting the device’s program in CABG patients recently exposed to ticagrelor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CytoSorbents posts investor presentation outlining Q2 revenue, cash burn progress toward breakeven

You may also like

Crypto prices